Intelligence · Patents
Patents expiring in 2042
Annual patent cliff calendar for 2042 — US pharmaceutical patents by expiration date.
- Patents
- 1,738
Quick answer
1,738 indexed pharmaceutical patents have expiration dates in 2042. Browse by soonest expiry with links to assignee companies and related drugs.
-
US 11253506
Compounds, compositions and methods for preventing and/or treating chlorine inhalation toxicity and/or injury
granted -
US 11254731
Viral vectors encoding recombinant FVIII variants with increased expression for gene therapy of hemophilia A
granted -
US 11253489
Visual cycle modulators
granted -
US 11253483
Protease assisted native-protein delivery approach (PANDA)
granted -
US 11253572
Use of a VEGF antagonist to treat angiogenic eye disorders
granted -
US 11253546
Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
granted -
US 11254752
Methods for treating cancer with bispecific anti-CD3xMUC16 antibodies and anti-PD-1 antibodies
granted -
US 11253511
Use of low dose emetine for inhibition of human cytomegalovirus (HCMV)
granted -
US 11253494
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
granted -
US 11253522
Cancer treatment targeted to tumor adaptive responses to protein synthesis stress
granted -
US 11253591
Combination of lenalidomide and polypeptide construct, and uses thereof
granted -
US 11253557
Therapeutic bacteriophage compositions
granted -
US 11254655
Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists
granted -
US 11254662
2′-halogenated-4′-thio-2′-deoxy-5-azacytidine analogs and use thereof
granted -
US 11254686
Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor
granted -
US 11254640
N-substituted indoles and other heterocycles for treating brain disorders
granted -
US 11254666
Compound as GLS1 inhibitor
granted -
US 11253509
Methods of treatment for cystic fibrosis
granted -
US 11253604
Conjugate of methotrexate and peptide
granted -
US 11253686
Swallowable drug delivery device and methods of drug delivery
granted -
US 11254667
Substituted imidazo[1,2-A]pyridines as IRAK 1/4 and flt3 inhibitors
granted -
US 11253445
Oxidative hair color remover in tablet or pellet form
granted -
US 11254725
Targeted therapeutic lysosomal enzyme fusion proteins and uses thereof
granted -
US 11254683
Selective inhibitors of protein arginine methyltransferase 5 (PRMT5)
granted -
US 11254735
Prevention of tissue ischemia and related methods
granted -
US 11254669
Fused imidazo-piperidine JAK inhibitors
granted -
US 11254739
Anti-human migration stimulating factor (MSF) and uses thereof
granted -
US 11254746
Anti-PD-1 monoclonal antibody, and preparation method therefor and application thereof
granted -
US 11254912
Methods and compositions for treating cancer
granted -
US 11254652
Crystalline forms of N-(4-(4-(cyclopropymethyl)piperazine-1-carbonyl)phenyl)quinoline-8-sulfonamide
granted -
US 11253508
PPARy agonist for treatment of progressive supranuclear palsy
granted -
US 11260092
Fungal immunogens and related materials and methods
granted -
US 11260120
Immunogenic composition comprising a fusion peptide derived from superantigen toxoids
granted -
US 11260050
Combination of cotinine plus antioxidant for treatment-resistant depression and correction of astrocytes functional deficit induced by depression and other neuropathological
granted -
US 11260070
Methods of treating feline coronavirus infections
granted -
US 11260073
Compounds and methods for modulating C90RF72
granted -
US 11261188
Fused heteroaryl compounds, and methods thereof for treating diseases, disorders, and conditions relating to aberrant function of a sodium channel
granted -
US 11261190
Dihydropyrimidine compounds and uses thereof in medicine
granted -
US 11261214
Bicyclic peptide ligand specific for CD137
granted -
US 11261230
Synthetic somatostatin receptor ligands
granted -
US 11260083
Compositions and methods for treating and preventing graft versus host disease
granted -
US 11261151
Methods for making and using endoxifen
granted -
US 11261248
Restricted immunoglobulin heavy chain mice
granted -
US 11260089
Products of manufacture comprising bacteriophages
granted -
US 11261152
Inhibitors of the N-terminal domain of the androgen receptor
granted -
US 11261237
Modified pigment epithelium-derived factor (PEDF) peptides and uses thereof for treating neovascular diseases, inflammatory diseases, cancer, and for cytoprotection
granted -
US 11261432
Method and composition for inducing human pluripotent stem cells
granted -
US 11261444
Organic compositions to treat EPAS1-related diseases
granted
Frequently asked questions
How many pharma patents expire in 2042?
1,738 published patents in our USPTO index have expiration dates falling in calendar year 2042.